Thibault Constance, Massard Christophe
Gustave-Roussy, département innovation thérapeutique et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Gustave-Roussy, département innovation thérapeutique et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Bull Cancer. 2015 Jun;102(6):501-8. doi: 10.1016/j.bulcan.2015.04.016. Epub 2015 May 26.
Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to revolutionize the treatment of metastatic castration resistant prostate cancer. Several other treatments are on trial targeting different pathways: androgene pathway (TAK-007, ARN-509, ODM-201, TOK-001), immune system (sipuleucel, ipilimumab, PROSTVAC-V/F, tasquinimod), but also tumor cell (PARP inhibitor, cabozantinib). The treatment sequencing will therefore soon be problematic, raising the necessity to identify predictive markers of response to the new therapies.
前列腺癌的治疗手段在数年间不断扩充。新型激素疗法，如醋酸阿比特龙或恩杂鲁胺，是首批彻底改变转移性去势抵抗性前列腺癌治疗方式的药物。其他几种治疗方法正在针对不同途径进行试验：雄激素途径（TAK - 007、ARN - 509、ODM - 201、TOK - 001）、免疫系统（sipuleucel、伊匹单抗、PROSTVAC - V/F、他喹莫德），还有肿瘤细胞（PARP抑制剂、卡博替尼）。因此，治疗顺序很快就会成为一个问题，这就使得识别对新疗法反应的预测标志物变得十分必要。
